Phase 4 N=17 Treatment

Effect of Age on Latanoprost 0.005% in Patients With Glaucoma

Glaucoma

Bottom Line

View on ClinicalTrials.gov: NCT00224289 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Dec 2012

Primary outcome: Primary: Pre-Treatment IOP (Intraocular Pressure) — 21.8 mm Hg

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Latanoprost 0.005% (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Yale University
Primary completion: Apr 2009

Outcome Measures

Outcome	Result	p-value
PRIMARY Pre-Treatment IOP (Intraocular Pressure)	21.8	—
PRIMARY Post-Treatment IOP (Intraocular Pressure)	18.3	—

Summary

Latanoprost is a commonly used treatment for glaucoma. Because of its mechanism of action, it is plausible that the age of a patient using the medication may affect its efficacy and time of onset. We are going to study the effectiveness of Latanoprost in people of different ages, to see if it changes based on the age of the patient.

Eligibility Criteria

Inclusion Criteria

diagnosis of open angle glaucoma,
pseudoexfoliation glaucoma, pigmentary glaucoma or ocular hypertension in one or both eyes;
IOP above their target pressure as determined by a glaucoma specialist;
willingness to participate in the study.

Exclusion Criteria

hypersensitivity to any of the components of the treatment medication;
previous use of topical prostaglandins;
documented ocular infection or intraocular inflammation within the past year;
previous filtering surgery or complicated cataract surgery;
active corneal disease;
presence of cystoid macular edema;
laser trabeculoplasty or any other ocular laser procedure within the past three months.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00224289). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.